创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels Biotechnology:3D Organoid Platform Function Introduction

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-04-16 14:57
  • Views:

(Summary description)With the rapid development of biotechnology, 3D organoid technology has gradually emerged as a new favorite in biomedical research. In this field, the 3D organoid platform of InnoModels Biotechnology has opened the door to real human physiology and disease mechanisms for researchers with its excellent key functions.

InnoModels Biotechnology:3D Organoid Platform Function Introduction

(Summary description)With the rapid development of biotechnology, 3D organoid technology has gradually emerged as a new favorite in biomedical research. In this field, the 3D organoid platform of InnoModels Biotechnology has opened the door to real human physiology and disease mechanisms for researchers with its excellent key functions.

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-04-16 14:57
  • Views:
Information

With the rapid development of biotechnology, 3D organoid technology has gradually emerged as a new favorite in biomedical research. In this field, the 3D organoid platform of InnoModels Biotechnology has opened the door to real human physiology and disease mechanisms for researchers with its excellent key functions.
First of all, the 3D organoid platform of InnoModels Biotechnology has excellent simulation capability. While traditional two-dimensional cell culture models often fail to fully simulate the complex environment of the real human body, 3D organoid technology is capable of constructing three-dimensional tissue structures that are closer to the real thing, thus more accurately simulating the physiological and pathological processes in the human body. This feature enables researchers to study the occurrence, development and treatment of diseases more realistically in an in vitro environment, improving the accuracy and reliability of research.
Secondly, 3D organoid platform of InnoModels Biotechnology is highly customizable. Different tissues and organs have unique structures and functions, while the 3D organoid platform of InnoModels is able to customize organoid models with specific structures and functions according to the needs of researchers. This customizability allows researchers to build the most suitable organoid models for specific research goals, thus improving research efficiency and results.

 


In addition, the 3D organoid platform from InnoModels Biotechnology is equipped with high-throughput processing capabilities. While traditional cell culture models often face time, space and resource constraints when processing large numbers of samples, the 3D organoid platform is able to process multiple samples at the same time through highly efficient production processes and technical means, thus greatly increasing the throughput of research. This high-throughput processing capability enables researchers to obtain a large amount of experimental data in a short period of time, accelerating the progress of research and the output of results.
Finally, the 3D organoid platform of InnoModels Biotechnology also has a wide range of application prospects. Whether in drug discovery, disease modeling or regenerative medicine, 3D organoid technology shows great potential and value. By constructing organoid models with specific structures and functions, researchers are able to gain a deeper understanding of the mechanisms and developmental processes of diseases, and thus develop more accurate and effective therapeutic methods. At the same time, 3D organoid technology can also provide important tools and resources to support regenerative medicine and promote the regeneration and repair of human tissues and organs.
In summary, 3D organoid platform of InnoModels Biotechnology has become an important tool in the field of biomedical research with its excellent simulation capability, high customizability, high-throughput processing capability and wide application prospects. With the continuous development and innovation of the technology, it is believed that the 3D organoid platform will bring more breakthroughs and surprises to researchers to promote the development and progress of the biomedical field.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司